Merck & Co Inc

NYSE: MRK
$117.17
-$0.06 (-0.1%)
Closing Price on September 20, 2024

MRK Articles

24/7 Wall St. has put together a preview of the Dow Jones Industrial Average companies scheduled to report their quarterly results this week.
The April 13 short interest data have been compared with the previous figures, and short interest moves in these selected pharmaceutical stocks were mixed.
The March 31 short interest data have been compared with the previous figures, and short interest decreased in most of these selected pharmaceutical stocks.
The March 15 short interest data have been compared with the previous figures, and short interest in most of these selected pharmaceutical stocks was mixed.
24/7 Wall St. has taken a look at a few companies within the health care sector that might have seen a reaction from the health care vote in Congress, or lack thereof.
DuPont, Chevron, Merck, and Pfizer sink the DJIA on Thursday.
Intel, GE, Merck, and Chevron weighed on the DJIA Monday.
The February 28 short interest data have been compared with the previous figures, and short interest in most of these selected pharmaceutical stocks decreased.
Chevron, Verizon, Pfizer, and Merck combined to weigh on the DJIA Tuesday.
Merck and Pfizer each saw their shares sink early on Monday after the firms gave an update on their type 2 diabetes treatment.
Judging by this report, short sellers are making a tremendous bet against Trump’s plan to reform the health care sector.
Merck saw its shares slip on Wednesday after the firm reported that it will be halting its mid-to-late-stage clinical trial for the treatment of Alzheimer’s disease.
JPMorgan, Apple, Merck, and Goldman Sachs all set new 52-week highs and dominated the rising DJIA on Tuesday.
It has yet to be seen how much headway Trump can actually make with heath care reforms, but so far the reaction has been quite positive.
Merck reported disappointing fourth-quarter financial results before the markets opened on Thursday.